DexCom — May 1, 2025 release

Exhibit 99.1 Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program SAN DIEGO - (BUSINESS WIRE-May 1, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: • Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic 1 basis. • U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic 1 basis, all on a year-over-year basis. • GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Quarter 2025 Strategic Highlights: • Secured broader coverage in the US with 2 of the 3 largest PBMs now covering Dexcom CGM for anyone with diabetes. • Expanded Stelo’s distribution footprint with launch on the Amazon storefront. • Shortly after the end of the quarter, received FDA clearance for Dexcom G7 15 Day System. “To start the year, Dexcom delivered a quarter of strong revenue results and unlocked significant new type 2 cov